Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes

被引:3
|
作者
Henrot, Pauline [1 ,2 ]
Pain, Catherine [1 ]
Taieb, Alain [1 ,3 ]
Truchetet, Marie-Elise [2 ,4 ]
Cario, Muriel [1 ,3 ]
机构
[1] Univ Bordeaux, INSERM, BMGIC, UMR1035, Batiment TP Zone Sud,4e Etage,146 Rue Leo Saignat, F-33076 Bordeaux, France
[2] Hop Pellegrin, Natl Reference Ctr Syst Autoimmune Rare Dis, Dept Rheumatol, Pl Amelie Raba Leon, Bordeaux, France
[3] Hop St Andre, Natl Ctr Rare Skin Disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France
[4] Univ Bordeaux, CNRS, Immunoconcept, UMR 5164, Bordeaux, France
关键词
CCN3; epidermis; keratinocytes; melanocytes; NOV; scleroderma; systemic sclerosisDear Editor; SKIN; MELANOCYTES; VITILIGO;
D O I
10.1111/pcmr.12912
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic sclerosis (SSc) is a severe disease whose pathophysiology remains partly unknown, combining autoimmune, vascular, and fibrotic features. Recently, we evidenced a link between vasculopathy and pigmentary changes in SSc. CCN3 (NOV) is a matricellular protein implicated in both angiogenesis and pigmentation regulation, in particular melanocyte adhesion to the basal layer. We decided to study CCN3 expression in SSc epidermis. We show that in SSc patients with pigmentary changes compared to patients with normal pigmentation, CCN3 is specifically downregulated in situ in melanocytes and upregulated in keratinocytes. Moreover, the number of melanocytes is significantly decreased in SSc patients with a disease duration of more than 5 years compared to the other patients. Altogether, our findings could provide new insights on the mechanisms of pigmentary changes in SSc patients, as well as treatment adaptation in a personalized manner.
引用
收藏
页码:895 / 898
页数:4
相关论文
共 50 条
  • [41] Evaluation of Changes in Corneal Biomechanics in Patients with Systemic Sclerosis
    Zimmermann, Nicole
    Brandt, Svea
    Bruenner, Jeanette
    Erb, Carl
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2019, 236 (06) : 806 - 815
  • [42] Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
    Chakravarty, Eliza F.
    Martyanov, Viktor
    Fiorentino, David
    Wood, Tammara A.
    Haddon, David James
    Jarrell, Justin Ansel
    Utz, Paul J.
    Genovese, Mark C.
    Whitfield, Michael L.
    Chung, Lorinda
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [43] HLA-G Expression in the Skin of Patients with Systemic Sclerosis
    Wastowski, Isabela J.
    Sampaio-Barros, Percival D.
    Amstalden, Eliane M. I.
    Palomino, Gustavo Martelli
    Marques-Neto, Joao Francisco
    Crispim, Janaina C. O.
    Biral, Ana C.
    Rassi, Diane M.
    Carosella, Edgardo D.
    Moreau, Philippe
    Donadi, Eduardo A.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) : 1230 - 1234
  • [44] CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1α-induced twist expression
    Chen, Po-Chun
    Tai, Huai-Ching
    Lin, Tien-Huang
    Wang, Shih-Wei
    Lin, Chih-Yang
    Chao, Chia-Chia
    Yu, Hong-Jeng
    Tsai, Yu-Chieh
    Lai, Yu-Wei
    Lin, Chiao-Wen
    Tang, Chih-Hsin
    ONCOTARGET, 2017, 8 (43) : 74506 - 74518
  • [45] Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis
    Yamada, Daisuke
    Asano, Yoshihide
    Takahashi, Takehiro
    Masui, Yuri
    Aozasa, Naohiko
    Akamata, Kaname
    Noda, Shinji
    Tamaki, Zenshiro
    Tada, Yayoi
    Sugaya, Makoto
    Sato, Shinichi
    Kadono, Takafumi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (03) : 351 - 357
  • [46] Effects of resveratrol and its analogue pterostilbene, on NOV/CCN3 adipokine in adipose tissue from rats fed a high-fat high-sucrose diet
    Trepiana, J.
    Gomez-Zorita, S.
    Fernandez-Quintela, Alfredo
    Gonzalez, M.
    Portillo, M. P.
    JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2019, 75 (03) : 275 - 283
  • [47] Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting
    van der Kroef, Maarten
    Castellucci, Monica
    Mokry, Michal
    Cossu, Marta
    Garonzi, Marianna
    Bossini-Castillo, Lara M.
    Chouri, Eleni
    Wichers, Catharina G. K.
    Beretta, Lorenzo
    Trombetta, Elena
    Silva-Cardoso, Sandra
    Vazirpanah, Nadia
    Carvalheiro, Tiago
    Angiolilli, Chiara
    Bekker, Cornelis P. J.
    Affandi, Alsya J.
    Reedquist, Kris A.
    Bonte-Mineur, Femke
    Zirkzee, Els J. M.
    Bazzoni, Flavia
    Radstake, Timothy R. D. J.
    Rossato, Marzia
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (04) : 529 - 538
  • [48] Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)
    Atamas, S. P.
    Luzina, I. G.
    Ingels, J.
    Choi, J.
    Wong, W. K.
    Furst, D. E.
    Clements, P. J.
    Postlethwaite, A. E.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (03) : 426 - 435
  • [49] Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis
    Hasegawa, Minoru
    Fujimoto, Manabu
    Matsushita, Takashi
    Hamaguchi, Yasuhito
    Takehara, Kazuhiko
    RHEUMATOLOGY, 2013, 52 (02) : 242 - 251
  • [50] Aberrant Chitinase 3-Like 1 Expression in Basal Cells Contributes to Systemic Sclerosis Fibrosis
    Wang, Xiuyuan
    Ye, Tianbao
    Huang, Junxia
    Hu, Feifei
    Huang, Chengjie
    Gu, Bei
    Xu, Xinzhi
    Yang, Ji
    ADVANCED SCIENCE, 2024,